Ocugen to Present at BIO International Convention 2024
May 29 2024 - 7:15AM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines, today
announced that the Company will present at the 2024 BIO
International Convention taking place in San Diego, CA from June 3
– 6, 2024.
During the conference, Ocugen’s leadership team will host
meetings with potential partners and pharmaceutical executives to
explore opportunities for the Company’s dynamic pipeline addressing
unmet medical needs—particularly its first-in-class ophthalmic
modifier gene therapy and regenerative cell therapy platforms.
“We are excited to return to BIO this year and showcase the
significant advancements we've achieved both clinically and
strategically,” said Dr. Shankar Musunuri, Chairman, CEO, and
Co-founder of Ocugen. “BIO is an important opportunity to pursue
collaborations that will propel the development of our
first-in-class therapies while also enhancing shareholder value. We
eagerly anticipate engaging with the distinguished industry
professionals in attendance.”
Ocugen’s modifier gene therapy platform recently achieved
several critical milestones, including the initiation of the OCU400
Phase 3 liMeLiGhT clinical trial for retinitis pigmentosa that
affects approximately 300,000 people in the U.S. and Europe
combined. Additionally, dosing was completed in Cohort 2 in both
the OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy
secondary to dry age-related macular degeneration (2-3 million
people in the U.S. and Europe combined) and OCU410ST Phase 1/2
GARDian trial for Stargardt disease (approximately 100,000 people
in the U.S. and Europe combined).
NeoCart® is the Company’s Phase 3-ready, pioneering regenerative
cell therapy candidate utilizing an enhanced autologous cartilage
repair approach. NeoCart has been shown to fully restore cartilage
in as little as 6 months in some patients. NeoCart is the only
autologous therapy utilizing a 3D scaffold and novel bioreactor to
simulate compressive force and enhance cartilage cell
differentiation. Recently, Ocugen completed its state-of the-art
cell and gene therapy manufacturing facility.
Ocugen’s presentation details are as
follows:
Event: BIO 2024 International Convention
Date: Monday, June 3, 2024 Time:
2:15 p.m. PT Location: Presentation Theater 1 -
Hall A - Exhibition Hall, San Diego Convention
CenterPresenter: Dr. Shankar Musunuri, Chairman,
CEO, and Co-founder
Please visit Ocugen at Booth #3945 to learn more about the
Company’s clinical programs and the potential they may hold for
patients.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patient’s lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us on X
and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
regarding qualitative assessments of available data, potential
benefits, expectations for ongoing clinical trials, anticipated
regulatory filings and anticipated development timelines, which are
subject to risks and uncertainties. We may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks, and uncertainties
that may cause actual events or results to differ materially from
our current expectations, including, but not limited to, the risks
that preliminary, interim and top-line clinical trial results may
not be indicative of, and may differ from, final clinical data;
that unfavorable new clinical trial data may emerge in ongoing
clinical trials or through further analyses of existing clinical
trial data; that earlier non-clinical and clinical data and testing
of may not be predictive of the results or success of later
clinical trials; and that that clinical trial data are subject to
differing interpretations and assessments, including by regulatory
authorities. These and other risks and uncertainties are more fully
described in our periodic filings with the Securities and Exchange
Commission (SEC), including the risk factors described in the
section entitled “Risk Factors” in the quarterly and annual reports
that we file with the SEC. Any forward-looking statements that we
make in this press release speak only as of the date of this press
release. Except as required by law, we assume no obligation to
update forward-looking statements contained in this press release
whether as a result of new information, future events, or
otherwise, after the date of this press release.
Contact:Tiffany HamiltonHead of
CommunicationsTiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2024 to Jun 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Jun 2023 to Jun 2024